

## **Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million**

**GHENT, Belgium – May 17, 2010** - Pronota NV today announced that it has raised an additional EUR 1.5 million in the final close of its Series B financing. The financing has been subscribed by MedSciences Capital, the venture capital arm of Kempen & Co, which is a specialized Dutch merchant bank. Pronota has raised a total of EUR 7.9 million in its Series B round, which has been subscribed by premier life sciences investors such as Gimv, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management Inc., Baekeland Fund and MedSciences Capital. Pronota is using the proceeds of the Series B financing to push forward its diagnostic development programs in the cardio-renal area, pre-eclampsia, sepsis, and ovarian cancer.

The results obtained so far in its cardio-renal and other programs provide extensive validation of Pronota's technology. Pronota now addresses a range of significant commercial opportunities, and is aiming to have its first product ready for launch in 2012.

### **About Pronota**

Pronota was founded in late 2004 to develop protein biomarker diagnostics derived from its proprietary platform that uniquely mines for low-abundance protein biomarkers in blood. In this short time, it has successfully implemented its technology and made substantial progress in its diagnostic product programs.

### **About MedSciences Capital**

MedSciences Capital (MSC) is a venture capital investor active in the field of the medical life sciences, providing equity financing to companies developing diagnostics, therapeutics, or medical devices for human use. MSC currently manages three funds: MedSciences Capital B.V., MedSciences Capital II B.V., and MedSciences Seed Fund B.V. All funds are closed-end funds. MSC operates as part of Kempen & Co N.V., a specialized merchant bank offering asset management, corporate finance, and security trading services in a number of selected fields, including the life sciences. Kempen & Co, in turn, is part of F. van Lanschot Bankiers N.V.

#### **Contact Pronota:**

Nick McCooke, CEO

Pronota NV  
Technologiepark 4  
VIB Bio-Incubator  
B-9052 Zwijnaarde / Ghent  
Belgium

Tel: +32 (0)9 241 11 64

[www.pronota.com](http://www.pronota.com)

#### **Contact MedSciences Capital:**

Otto Postma, Senior Investment Manager

MedSciences Capital  
Beethovenstraat 300  
1077 WZ Amsterdam  
The Netherlands

Tel: +31 (0)20 348 8752

[www.medsciencescapital.com](http://www.medsciencescapital.com)